U.S. Markets open in 14 mins

CymaBay Therapeutics: What Investors Should Watch For

Margaret Patrick
CymaBay Therapeutics: What Investors Should Watch For

CymaBay Therapeutics (CBAY) is currently enrolling patients in its Phase 3 registrational trial, ENHANCE, to evaluate the use of its investigational PPARδ (peroxisome proliferator-activated receptor delta) agonist, seladelpar, in PBC (primary biliary cholangitis).